Acute Myeloblastic Leukemia Type 1

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Status:
Terminated
Last Changed:
Apr 4, 2017
First Changed:
Nov 4, 2011
Disease(s):
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention(s):
bortezomib
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Jul 2, 2017
First Changed:
Apr 27, 2011
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
cyclosporinepravastatin sodiummitoxantrone hydrochlorideetoposidebone marrow aspiration
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Active, not recruiting
Last Changed:
Dec 13, 2018
First Changed:
Mar 12, 2014
Disease(s):
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention(s):
clofarabinedaunorubicin hydrochlorideclinical observationcytarabinedecitabinelaboratory biomarker analysisquality-of-life assessmentquestionnaire administration

Connect. Empower. Inspire.